Skip to main content

How well does Trogarzo work to treat multidrug-resistant (MDR) HIV-1?

Medically reviewed by Last updated on Sep 28, 2022.

Official answer


Trogarzo (ibalizumab-uiyk) was studied in a clinical trial of 40 multidrug-resistant (MDR) HIV-1 infection patients with high HIV virus levels. These patients had already received multiple other HIV treatments (some patients had received 10 or more). Most patients (33 of the 40 patients, or 83%) experienced a significant decrease in their HIV-RNA levels one week after Trogarzo was added to their ineffective antiretroviral regimens. After 24 weeks of Trogarzo plus other antiretroviral drugs, 43% of the trial’s participants achieved HIV RNA suppression.

Related medical questions

Drug information

Related support groups